More recently Brand et al.[31] report that inhibition of nuclear EGFR translocation leads to a subsequent accumulation of EGFR on the plasma membrane, which has been observed to enhance sensitivity of triple negative breast cancer cells to cetuximab [32]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.